The AI Revolution in Life Sciences: Technologies, Applications, and Future Directions

CHAPTER 8

Future Trends and Emerging Innovations in AI and Life Sciences

132

8.1 AI AND QUANTUM COMPUTING IN LIFE SCIENCES

The convergence of Artificial Intelligence (AI) and quantum computing (QC) represents one of the most promising emerging directions in life sciences. AI has already transformed areas such as drug discovery, biomedical imaging, genomics, clinical decision support, and personalized medicine by enabling computers to identify patterns and relationships in large and complex datasets. Quantum computing, in contrast, introduces a fundamentally different computational paradigm based on quantum-mechanical principles such as superposition and entanglement. The combination of these technologies could eventually enable researchers to address biological and chemical problems that remain difficult or computationally expensive for conventional computers. (Figure 8.1)

Figure 8.1: AI and Quantum Computing in Life Sciences

Modern life-science research generates enormous quantities of heterogeneous data, including genomic sequences, protein structures, molecular interactions, electronic health records, medical images, and clinical-trial data. Conventional AI and deep-learning methods have become increasingly effective at extracting useful information from these datasets. In drug discovery, for

133

example, deep learning is being used for molecular property prediction, virtual screening, molecular generation, and structure-based drug design (Tropsha et al., 2024).

Computational approaches have also expanded the ability of researchers to screen extremely large virtual libraries of drug-like molecules and prioritize promising candidates before laboratory testing (Sadybekov & Katritch, 2023). Nevertheless, many biological systems involve highly complex molecular interactions that remain challenging to model accurately.

Quantum computing could complement AI by providing new approaches for representing and solving certain computational problems. Unlike classical computers, which process information using bits represented as 0 or 1, quantum computers use qubits that can exist in quantum superpositions. Quantum algorithms may therefore provide computational advantages for selected classes of problems, although practical advantages in life-science applications have not yet been demonstrated broadly. The most important near-term opportunity is likely to involve hybrid quantum-classical computing, in which quantum processors perform particular computational tasks while classical computers and AI systems handle data preparation, optimization, and interpretation.

One particularly important application is molecular simulation and drug discovery. The behavior of molecules is fundamentally governed by quantum mechanics, making accurate simulation computationally demanding as molecular complexity increases. Quantum computers could potentially provide more efficient representations of molecular electronic structures and chemical interactions. At the same time, AI can learn relationships between molecular structures and properties from experimental and computational datasets. Combining AI with quantum methods could therefore improve molecular property prediction, binding-affinity estimation, virtual screening, and de novo drug design. Recent research on quantum machine learning (QML) has specifically explored quantum neural networks, variational quantum circuits, molecular property prediction, and molecular generation for drug discovery (Smaldone et al., 2025).

134

Another promising area is protein and biomolecular modelling. Proteins have highly complex three-dimensional structures and dynamic interactions with other molecules. AI-based protein-structure prediction has demonstrated the value of machine learning for understanding biological macromolecules, while quantum computing may eventually contribute to more detailed simulations of molecular interactions. The combination could support improved prediction of protein–ligand interactions and facilitate the development of therapeutic molecules with greater specificity. Neural-network approaches to quantum chemistry are also being investigated as a means of approximating complex electronic wavefunctions and molecular properties (Hermann et al., 2023).

Genomics and precision medicine represent another potential frontier. Genome-scale datasets contain enormous numbers of genetic variables, and AI can identify patterns associated with disease susceptibility, treatment response, and biological traits. Quantum algorithms could eventually be investigated for selected optimization, pattern-recognition, or genomic-analysis tasks. However, the current evidence does not support the assumption that quantum machine learning is already superior to classical machine learning for large-scale healthcare datasets. A systematic review of QML for digital health found limited rigorous evidence of empirical quantum advantage and highlighted important challenges related to data encoding, scalability, and realistic quantum-hardware constraints (Gupta et al., 2025). Therefore, quantum genomics should currently be viewed as an emerging research direction rather than an established clinical technology.

The AI–quantum combination may be particularly valuable because AI can help overcome some limitations of quantum systems. Quantum processors currently suffer from noise, limited qubit numbers, error rates, and difficulties in scaling. Machine-learning techniques can potentially assist with quantum error mitigation, circuit optimization, parameter tuning, and interpretation of quantum outputs. Conversely, quantum processors could eventually accelerate selected computational tasks involved in training or executing AI models. This creates a feedback loop in which AI improves quantum computing while quantum computing potentially expands the capabilities of AI.

Despite its promise, several challenges must be addressed before these technologies can become routine in life-science research. Quantum hardware

135

remains immature, and many proposed algorithms have only been demonstrated through simulations or small-scale experiments. Biological datasets are also highly heterogeneous and frequently contain missing, biased, or noisy information. Furthermore, transferring quantum algorithms from laboratory demonstrations to clinically meaningful applications requires reliable benchmarks and evidence of real-world benefit. Recent research emphasizes the importance of evaluating QML under realistic hardware conditions rather than relying solely on theoretical performance claims (Gupta et al., 2025). Similarly, current AI-driven drug-discovery research continues to face challenges in translating computational predictions into experimentally and clinically validated outcomes.

Looking ahead, the most realistic pathway is likely to be incremental integration rather than immediate replacement of classical computing. Classical AI will continue to dominate many applications because of its maturity, accessibility, and scalability. Quantum computing is more likely to enter specialized parts of the life-science pipeline where its computational characteristics provide a demonstrable advantage. Hybrid platforms could connect AI models, classical high-performance computing, quantum processors, laboratory automation, and real-world experimental data into integrated discovery systems.

Ultimately, the convergence of AI and quantum computing could contribute to a new generation of AI-driven scientific discovery. Potential long-term applications include faster drug development, improved molecular simulation, personalized treatment selection, advanced biomarker discovery, and more efficient modelling of complex biological systems. However, expectations should remain evidence-based. Quantum computing should not be regarded as a guaranteed solution to every computational problem in life sciences. Its significance will depend on advances in hardware, quantum algorithms, data integration, error correction, and rigorous validation. If these challenges are successfully addressed, AI and quantum computing could evolve from experimental technologies into complementary components of the future life-science research ecosystem.

136

8.2 DIGITAL HEALTH, IOT, AND SMART BIOLOGICAL SYSTEMS

The convergence of artificial intelligence (AI), digital health, the Internet of Things (IoT), wearable sensors, cloud computing, and biological data analytics is transforming modern life sciences. Rather than treating healthcare as a sequence of isolated clinical encounters, these technologies are creating continuously connected systems in which physiological, environmental, behavioral, and molecular information can be collected, analyzed, and translated into actionable insights. The World Health Organization (WHO) recognizes digital health as an important component of stronger, more equitable, and people-centred health systems. In 2025, the WHO extended its Global Strategy on Digital Health through 2027, reflecting the increasing importance of digital technologies in health-system transformation (WHO, 2025a). (Figue 8.2)

Figure 8.2: Digital Health, IoT, and Smart Biological Systems

8.2.1 Digital Health and Intelligent Healthcare

Digital health encompasses technologies such as electronic health records, telemedicine, mobile health applications, clinical decision-support systems, remote monitoring, digital therapeutics, and AI-enabled diagnostic tools. AI

137

adds an analytical layer to these systems by identifying patterns in large and complex datasets that may not be readily detectable through conventional approaches. Such systems can support disease prediction, risk stratification, medical imaging, personalized treatment, and clinical workflow optimization. The U.S. Food and Drug Administration (FDA) notes that AI/ML technologies can contribute to early disease detection, diagnosis, prognosis, risk assessment, and the identification of new patterns in physiology and disease progression (FDA, 2025a).

An important future direction is the movement from reactive healthcare toward predictive and preventive healthcare. Instead of waiting for symptoms to become clinically significant, AI systems can analyze longitudinal information to identify changes in an individual's health trajectory. For example, continuous monitoring of heart rate, activity, sleep, glucose, oxygen saturation, or other physiological parameters can help identify abnormalities at an earlier stage. However, these systems must be designed around data quality, interoperability, transparency, privacy, and clinical validation. WHO emphasizes that responsible AI adoption requires appropriate governance, ethical standards, regulation, and attention to equity (WHO, 2024).

8.2.2 IoT and Connected Biological Monitoring

The Internet of Things provides the technological infrastructure through which physical devices can communicate and exchange data. In healthcare and life sciences, IoT can connect wearable devices, implantable sensors, smart medical equipment, laboratory instruments, environmental monitors, and hospital information systems.

These devices generate continuous streams of data that can be transmitted to cloud or edge-computing platforms, where AI algorithms can process them in real time.

AI-based wearable sensors represent an important development in this area. Wearable technologies can collect physiological and behavioral information while individuals perform normal daily activities. Machine-learning models can subsequently convert raw sensor signals into meaningful health indicators, enabling applications in fitness monitoring, chronic disease management,

138

rehabilitation, elderly care, and early detection of physiological abnormalities (Shajari et al., 2023).

The future of IoT-enabled healthcare is likely to involve increasingly unobtrusive and intelligent sensors. Flexible electronics, biosensors, smart textiles, implantable devices, and miniaturized monitoring systems may allow biological information to be collected continuously with minimal disruption to patients. Such technologies can also contribute to remote healthcare, particularly for individuals who have limited access to specialized clinical facilities.

8.2.3 Smart Biological Systems

Smart biological systems represent a broader concept in which biological entities, sensors, computational models, and AI interact dynamically. These systems may operate at different scales, from molecular and cellular processes to tissues, organs, individuals, and populations. AI can integrate heterogeneous information, including genomic, transcriptomic, proteomic, imaging, clinical, environmental, and behavioral data, to generate more comprehensive representations of biological systems.

One particularly promising development is the emergence of digital twins in healthcare. A digital twin is a dynamic virtual representation connected to a physical individual, organ, disease, or biological system through continuous data exchange. Unlike a static digital model, a sophisticated health digital twin can incorporate real-time information and use AI, simulation, and predictive analytics to estimate future states and evaluate potential interventions (Katsoulakis et al., 2024).

Human-body digital twins could eventually support personalized treatment planning, surgical simulation, disease progression modelling, drug-response prediction, and individualized health management. Current research has already explored digital twins for areas such as oncology, cardiology, clinical trials, drug discovery, medical-device development, and personalized medicine. A systematic review published in 2024 found that digital-twin interventions showed beneficial outcomes across several areas of precision health, although the technology remains at an evolving stage (Shen et al.,

2024). 139

8.2.4 Future Directions and Challenges

The integration of digital health, IoT, and smart biological systems will increasingly depend on interoperability between devices, healthcare institutions, databases, and AI platforms. Standardized data formats and secure data-sharing mechanisms will be essential for creating reliable interconnected ecosystems. At the same time, cybersecurity will become increasingly important because connected medical devices and biological datasets contain highly sensitive information.

Another major challenge is algorithmic bias and reliability. AI models trained on incomplete or unrepresentative datasets may produce inaccurate predictions for certain populations. Consequently, future systems will require continuous validation, transparent documentation, human oversight, and lifecycle monitoring. The FDA's recent guidance initiatives emphasize transparency, bias management, documentation, and lifecycle considerations for AI-enabled medical devices (FDA, 2025b).

Ultimately, the convergence of AI, IoT, digital health, and biological modelling is likely to shift life sciences toward continuously learning and increasingly personalized systems. The long-term objective is not simply to automate healthcare but to establish intelligent environments capable of sensing biological changes, interpreting complex information, predicting risks, and supporting timely interventions. If technological innovation is accompanied by strong governance, ethical safeguards, interoperability, and equitable access, smart biological systems could become a foundational component of next-generation precision and preventive healthcare.

8.3 AI IN PANDEMIC PREDICTION AND GLOBAL HEALTH

The COVID-19 pandemic demonstrated that infectious disease outbreaks can develop rapidly and create consequences that extend far beyond the health sector. Early identification of emerging outbreaks is therefore a central component of global health security. Artificial intelligence (AI), particularly machine learning (ML), deep learning (DL), natural language processing (NLP), and predictive analytics, is increasingly being explored as a means of strengthening disease surveillance, forecasting transmission, identifying high-risk populations, and supporting public-health decision-making. Recent research indicates that the integration of diverse data sources with AI can

140

improve the development of early-warning systems for infectious diseases (Hu et al., 2025; Rodríguez et al., 2024). (Figure 8.3)

Figure 8.3: AI in Pandemic Prediction and Global Health

8.3.1 AI-Based Pandemic Prediction

Traditional epidemic forecasting generally relies on epidemiological models that describe disease transmission through parameters such as infection rates, recovery rates, population susceptibility, and contact patterns. These approaches remain highly valuable, but they can be difficult to adapt when information is incomplete or when an emerging pathogen behaves differently from previously observed diseases. AI-based models provide an additional approach because they can identify complex relationships within large and heterogeneous datasets.

Machine learning algorithms can process historical disease records, demographic information, environmental variables, mobility patterns, healthcare utilization, vaccination coverage, and other indicators to estimate the probability and potential scale of an outbreak. Deep-learning approaches can identify nonlinear patterns that may be difficult to detect using conventional statistical techniques. Research on epidemic forecasting 141

increasingly emphasizes data-centric approaches in which model performance depends not only on the sophistication of the algorithm but also on the quality, coverage, timeliness, and integration of the underlying data (Rodríguez et al.,

2024). AI can also support early-warning surveillance by continuously examining information from multiple sources. These may include laboratory reports, hospital admissions, syndromic surveillance, wastewater measurements, genomic surveillance, environmental information, news reports, search activity, and social media. Internet-based surveillance systems can provide signals that complement conventional public-health reporting and potentially identify unusual disease activity before complete clinical datasets become available (McClymont et al., 2024).

8.3.2 Role of NLP and Real-Time Data

Natural language processing has particular importance for pandemic intelligence because substantial amounts of health-related information are generated in unstructured textual formats. AI systems can examine news articles, health-agency announcements, scientific publications, online reports, and other textual sources to identify references to unusual disease events. Automated language analysis can classify reports according to disease, geographic location, severity, and temporal characteristics, helping public-health professionals prioritize potentially important signals.

However, information obtained from online platforms must be interpreted cautiously. Social media and internet data may contain misinformation, duplicate reports, geographical bias, and changes in user behavior that are unrelated to actual disease transmission. Consequently, AI-generated signals should normally be combined with laboratory, clinical, epidemiological, and environmental evidence rather than treated as definitive evidence of an outbreak. Reviews of infectious-disease early-warning systems emphasize the importance of integrating multiple sources of information rather than depending on a single indicator (Hu et al., 2025).

8.3.3 AI, Genomic Surveillance, and Variant Prediction

The increasing availability of pathogen genomic data creates another important application area for AI. Genomic surveillance enables researchers to

142

identify mutations and monitor the emergence and geographical distribution of pathogen variants. AI and computational methods can help analyze large genomic datasets, classify genetic patterns, and support assessment of potential changes in pathogen behavior.

During and after COVID-19, the combination of laboratory science, genomic surveillance, data analytics, and AI demonstrated the potential of technology-supported pandemic intelligence.

Future systems are likely to connect genomic information with epidemiological and clinical datasets to provide a more comprehensive understanding of emerging pathogens. Such integration could help researchers identify unusual genetic changes and prioritize variants for further laboratory and epidemiological investigation.

8.3.4 AI for Global Health Decision-Making

The value of pandemic prediction is ultimately determined by whether predictions can support timely action. AI systems can assist governments and health organizations in estimating potential healthcare demand, identifying regions at increased risk, planning medical supplies, allocating healthcare personnel, and evaluating possible intervention strategies. During COVID-19, AI applications were explored for forecasting, diagnosis, decision support, drug repurposing, and outbreak management (Alowais et al., 2024).

For example, an AI forecasting system could indicate that a particular region has a rising probability of increased infections over the following weeks. Public-health authorities could then use this information to increase testing capacity, strengthen hospital preparedness, improve communication, prepare essential medicines, or intensify surveillance. AI therefore has greater value when incorporated into a broader decision-making framework rather than functioning as an isolated prediction tool.

The World Health Organization (WHO) has emphasized that AI already has applications across disease surveillance, outbreak response, healthcare, and health-system management. At the same time, WHO stresses the importance of safety, equity, governance, and responsible implementation so that technological innovation does not increase existing health inequalities (WHO,

2024). 143

8.3.5 Challenges and Limitations

Despite its potential, AI cannot guarantee accurate prediction of the next pandemic. One major challenge is data quality. Disease surveillance data may be incomplete, delayed, inconsistent, or unavailable in low-resource settings. AI models trained primarily on data from high-income countries may therefore perform poorly when applied to different populations and healthcare systems.

Another challenge is model uncertainty. A highly accurate model under historical conditions may fail when a new pathogen emerges or when human behavior changes substantially. Pandemic conditions can produce unprecedented situations for which historical training data provide limited guidance. Researchers therefore increasingly emphasize robust evaluation, uncertainty estimation, external validation, and continuous updating of forecasting systems (Rodríguez et al., 2024).

Privacy and ethical concerns are also important. Pandemic surveillance may involve sensitive health, mobility, location, or demographic information. Appropriate governance mechanisms are required to ensure that data are collected and used proportionately, securely, and transparently. WHO's approach to AI for health emphasizes governance and standards intended to promote trustworthy and equitable adoption of AI technologies.

8.3.6 Future Directions

The future of AI-enabled pandemic prediction will likely involve multimodal and collaborative intelligence. Instead of relying on a single data source, future platforms may combine clinical records, genomic sequences, wastewater surveillance, climate data, mobility information, laboratory results, satellite observations, and online information. Advanced AI models may then generate continuously updated risk assessments for countries and regions.

Another important development will be the integration of AI with global collaborative surveillance networks. The WHO Hub for Pandemic and Epidemic Intelligence was established to strengthen the world's ability to detect, prepare for, and respond to health threats through data science, AI, laboratory detection, and collaborative surveillance. Future systems could increasingly connect national surveillance platforms so that emerging signals are identified and shared more rapidly across borders.

144

AI may therefore become an important component of a global early-warning ecosystem, but it should complement rather than replace epidemiologists, clinicians, laboratory scientists, public-health officials, and policymakers. The most effective approach will combine computational intelligence with human expertise, reliable surveillance infrastructure, transparent governance, and international cooperation.

WHO's research priorities for pandemic and epidemic intelligence similarly emphasize high-quality evidence and improved translation of surveillance research into informed public-health decisions (WHO, 2024).

Overall, AI has the potential to transform pandemic preparedness from a predominantly reactive model toward a more predictive and proactive system. Its greatest contribution may not be predicting exactly when or where the next pandemic will occur, but identifying weak signals earlier, estimating potential risks, improving preparedness, and helping decision-makers act before an outbreak becomes a global crisis.

8.4 FUTURE RESEARCH DIRECTIONS AND EMERGING INNOVATIONS

Figure 8.4: Future Research Directions and Emerging Innovations

145

Artificial intelligence (AI) is rapidly transforming life sciences from a collection of specialized computational applications into an increasingly integrated, data-driven scientific ecosystem. Future research is expected to move beyond conventional machine-learning models toward foundation models, multimodal AI, generative systems, autonomous research agents, digital twins, and AI-assisted experimental platforms. These developments have the potential to accelerate biological discovery, improve disease prediction, personalize treatment, and reduce the time and cost associated with drug and biotechnology development. At the same time, future research must address limitations related to data quality, interpretability, validation, privacy, bias, and responsible governance.

One of the most important future directions is the development of biological foundation models. Unlike conventional AI systems designed for a single task, foundation models can be pretrained on very large datasets and subsequently adapted to different biological applications. Such models can learn representations from DNA and RNA sequences, proteins, molecular structures, biomedical literature, clinical records, and other biological data. Their future development is likely to involve increasingly specialized models for genomics, proteomics, drug discovery, pathology, and clinical medicine. Foundation models are particularly promising because biological datasets frequently contain large amounts of unlabeled information, while high-quality annotation can be expensive and time-consuming (Li et al., 2024).

The next generation of models is therefore expected to combine self-supervised learning with biological knowledge and experimental evidence.

A second major research direction is multimodal AI. Biological phenomena are inherently multidimensional and cannot always be understood from a single data type. Future AI systems will increasingly integrate genomic sequences, transcriptomic profiles, proteomic information, medical images, electronic health records, physiological signals, and environmental data. Large multimodal models could allow researchers to examine relationships between molecular mechanisms and clinical outcomes within a unified computational framework. The World Health Organization (WHO, 2024) recognizes large multimodal models as an emerging technology with potential applications in healthcare, scientific research, public health, and drug development. However,

146

the reliability of multimodal systems will depend on the quality and compatibility of the underlying datasets.

AI-driven drug discovery and molecular design will remain another important area of innovation. Traditional drug development involves lengthy processes of target identification, compound screening, optimization, preclinical testing, and clinical evaluation. AI can support these stages by predicting molecular properties, identifying potential drug targets, generating candidate molecules, and estimating interactions between drugs and biological targets. AlphaFold 3 demonstrates the direction in which this field is moving: its unified deep-learning architecture can model complexes involving proteins, nucleic acids, small molecules, ions, and modified residues, expanding AI-assisted structural biology beyond protein structure prediction alone (Abramson et al., 2024). Future research may combine generative chemistry, molecular simulation, structural prediction, and experimental robotics to create iterative design–test– learn cycles.

Another emerging direction is the development of AI-generated biological hypotheses and autonomous scientific discovery. Rather than merely analyzing existing datasets, future AI systems may help formulate hypotheses, identify relationships that have not previously been recognized, recommend experiments, and interpret experimental results. This could create a new form of human–AI collaboration in which scientists provide research objectives while AI systems assist with literature analysis, experimental design, computational modelling, and prioritization of promising hypotheses. Such systems could substantially increase the speed of research; however, experimental verification will remain essential because computational predictions should be treated as testable hypotheses rather than definitive scientific conclusions (Richardson et al., 2024).

Digital twins and virtual biological models represent another promising research frontier. A digital twin is a computational representation of a biological system that can be continuously updated using relevant data. In life sciences, future digital twins could represent patients, organs, tumors, or cellular systems. Patient-level digital twins may eventually integrate medical history, imaging, genomics, laboratory measurements, and physiological signals to simulate disease progression or compare potential treatment

147

strategies. At the cellular level, AI-based models could help researchers investigate how genetic and environmental changes influence cellular behavior. Achieving this vision will require substantial advances in causal modelling, longitudinal data integration, mechanistic biology, and computational simulation.

Future research will also increasingly focus on AI-assisted precision medicine. Current clinical AI applications frequently concentrate on individual tasks, such as image classification or disease prediction. Future systems are expected to integrate multiple sources of patient information to support individualized risk assessment, diagnosis, treatment selection, and monitoring. The objective will be to move from population-level predictions toward models that can account for individual biological variation. Nevertheless, successful implementation will require prospective clinical validation, interoperability with healthcare systems, robust evaluation across demographic groups, and mechanisms for clinician oversight.

The integration of AI with laboratory automation and robotics may further change the research process. Automated laboratories can perform repetitive experiments, collect measurements, and feed experimental results back into computational models. Combined with AI, these systems could continuously select the next experiment based on previous outcomes. Such closed-loop systems may be particularly valuable in drug discovery, synthetic biology, protein engineering, and microbiology.

AI would therefore become not only a tool for analysing scientific data but also a component of an automated experimental discovery cycle.

Finally, responsible and trustworthy AI must remain a central research priority. As AI becomes more influential in healthcare and biological research, questions of privacy, fairness, transparency, accountability, explainability, and safety will become increasingly important. WHO guidance emphasizes that AI for health should be developed and deployed with appropriate ethical and governance safeguards (WHO, 2021; WHO, 2024). Future research should therefore develop standardized benchmarks, explainability techniques, bias-detection methods, privacy-preserving learning, reproducible evaluation

148

frameworks, and regulatory approaches that can keep pace with technological development.

Overall, the future of AI in life sciences is likely to be characterized by greater integration rather than isolated applications. Foundation models, multimodal systems, generative AI, molecular design platforms, digital twins, autonomous laboratories, and precision medicine may increasingly operate as interconnected components of a single research ecosystem. The most important challenge will not simply be developing more powerful AI models, but ensuring that these systems generate scientifically reliable, clinically meaningful, reproducible, and ethically responsible outcomes. The convergence of computational intelligence with experimental biology therefore has the potential to reshape how biological knowledge is generated and translated into practical solutions.

149

REFERENCES

• On digital twins in bioprocessing: Opportunities and limitations. (2025). Process Biochemistry, 156, 274–299. https://doi.org/10.1016/j.procbio.2025.05.023

• U.S. Department of Health & Human Services. (2026). The Security Rule. HHS.

• Vasey, B., Lippert, K. A. N., Khan, D. Z., et al. (2023). Intraoperative applications of artificial intelligence in robotic surgery: A scoping review of current development stages and levels of autonomy. Annals of Surgery, 278(6), 896–903. https://doi.org/10.1097/SLA.0000000000005700

• World Health Organization. (2021). Ethics and Governance of Artificial Intelligence for Health: WHO Guidance. World Health Organization.

• Yang, Y., Zhang, H., Gichoya, J. W., et al. (2024). The limits of fair medical imaging AI in real-world generalization. Nature Medicine, 30, 2838–2848. https://doi.org/10.1038/s41591-024-03113-4

• Yi, L., Wang, W., Diao, Y., Yi, S., Shang, Y., Ren, D., Ge, K., Gu, Y., et al. (2024). Recent advances of artificial intelligence in quantitative analysis of food quality and safety indicators: A review. TrAC Trends in Analytical Chemistry, 180, 117944. https://doi.org/10.1016/j.trac.2024.117944

• Zhu, L., Spachos, P., Pensini, E., & Plataniotis, K. N. (2021). Deep learning and machine vision for food processing: A survey. arXiv. https://arxiv.org/abs/2103.16106

• Abioye, E. A., et al. (2024). The application of machine learning techniques for smart irrigation systems: A systematic literature review. Smart Agricultural Technology, 7, 100425. https://doi.org/10.1016/j.atech.2024.100425.

• Abramson, J., Adler, J., Dunger, J., et al. (2024). Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature, 630, 493–500. https://doi.org/10.1038/s41586-024-07487-w.

• Abudayyeh, O. O., & Gootenberg, J. S. (2024). Programmable biology through artificial intelligence: From nucleic acids to proteins to cells. Nature Methods, 21, 1384–1386. https://doi.org/10.1038/s41592-024- 02338-y

• Acosta, J. N., Falcone, G. J., Rajpurkar, P., & Topol, E. J. (2022). Multimodal biomedical AI. Nature Medicine, 28, 1773–1784. https://doi.org/10.1038/s41591-022-01981-2 150

• Alam, M. A., et al. (2024). Artificial intelligence as a tool in drug discovery and development. World Journal of Experimental Medicine. https://doi.org/10.5493/wjem.v14.i4.99.

• Alowais, S. A., Alghamdi, S. S., Alsuhebany, N., Alqahtani, T., Alshaya, A. I., Almohareb, S. N., Aldairem, A., Alrashed, M., Bin Saleh, K., and Badreldin, H. A. (2024). Innovative applications of artificial intelligence during the COVID-19 pandemic. Infectious Medicine, 3(1), 100095. https://doi.org/10.1016/j.imj.2024.100095.

• Applications of Artificial Intelligence in Biotech Drug Discovery and Product Development. (2025). Review of AI applications in small-molecule design, protein binders, antibody engineering, and biopharmaceutical product development.

• Ardila, D., Kiraly, A. P., Bharadwaj, S., et al. (2019). End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. Nature Medicine, 25(6), 954–961. https://doi.org/10.1038/s41591-019-0447-x

• Ashley, E. A. (2016). Towards precision medicine. Nature Reviews Genetics, 17, 507–522. https://doi.org/10.1038/nrg.2016.86

• Aversano, L., Bernardi, M. L., Cimitile, M., & Iammarino, M. (2024). A systematic review on artificial intelligence approaches for smart health devices. Journal of Medical Systems, 48, 1–21.

• Bagga, M. (2024). Image-based detection and classification of plant diseases using deep learning: State-of-the-art review. Urban Agriculture & Regional Food Systems, 9(1), e20053. https://doi.org/10.1002/uar2.20053.

• Ben Abbes, A., Jarray, N., & Farah, I. R. (2024). Advances in remote sensing based soil moisture retrieval: Applications, techniques, scales and challenges for combining machine learning and physical models. Artificial Intelligence Review, 57, 224. https://doi.org/10.1007/s10462-024-10734-1.

• Ben Abbes, A., Jarray, N., & Farah, I. R. (2024). Advances in remote sensing based soil moisture retrieval: Applications, techniques, scales and challenges for combining machine learning and physical models. Artificial Intelligence Review, 57, 224. https://doi.org/10.1007/s10462-024-10734-1

• Cella, L., Lin, J., Goldenberg, M. G., & Hung, A. J. (2026). The future of robotic surgery in the age of artificial intelligence. Nature Reviews Urology. https://doi.org/10.1038/s41585-026-01153-8 151

• Char, D. S., Shah, N. H., & Magnus, D. (2018). Implementing machine learning in health care-Addressing ethical challenges. New England Journal of Medicine, 378(11), 981–983. https://doi.org/10.1056/NEJMp1714229

• Chee, S. W., et al. (2026). Hit identification in ultra large virtual screening: An integrative review and future challenges. Drug Discovery Today. https://doi.org/10.1016/j.drudis.2026.104616

• Cheng, T., Li, Q., Zhou, Z., Wang, Y., & Bryant, S. H. (2012). Structure-based virtual screening for drug discovery: A problem-centric review. The AAPS Journal, 14(1), 133–141. https://doi.org/10.1208/s12248-012-9322-0

• Deep learning based abiotic crop stress assessment for precision agriculture: A comprehensive review. (2025). Journal of Environmental Management, 125158.

• Demissie, W. A., Sebastiani, L., & Rossetto, R. (2026). Integration of artificial intelligence and remote sensing for crop yield prediction and crop growth parameter estimation in Mediterranean agroecosystems: Methodologies, emerging technologies, research gaps, and future directions. European Journal of Agronomy, 173, 127894.

• Deng, J., Yang, Z., Ojima, I., Samaras, D., & Wang, F. (2021). Artificial intelligence in drug discovery: Applications and techniques. arXiv. https://arxiv.org/abs/2106.05386.

• Di Blasi, R., Gabrielli, J., Shabestary, K., et al. (2024). Understanding resource competition to achieve predictable synthetic gene expression in eukaryotes. Nature Reviews Bioengineering, 2, 721–732.

• Ding, C., Ou Yang, O., & Ierapetritou, M. G. (2024). Towards digital twin for biopharmaceutical processes: Concept and progress. In Biopharmaceutical Manufacturing (pp. 179–211). Springer.

• Du, Y., Jamasb, A. R., Guo, J., et al. (2024). Machine learning-aided generative molecular design. Nature Machine Intelligence, 6, 589–604. https://doi.org/10.1038/s42256-024-00843-5

• Dunn, A. L., Burgess, S. J., & Garcia Martin, H. (2020). Machine learning for metabolic engineering: A review. Metabolic Engineering, 63, 1–15. https://doi.org/10.1016/j.ymben.2020.10.005.

• Duong-Trung, N., Born, S., Kim, J. W., et al. (2022). When bioprocess engineering meets machine learning: A survey from the perspective of automated bioprocess development. arXiv. 152

• Eraslan, G., Avsec, Ž., Gagneur, J., & Theis, F. J. (2019). Deep learning: New computational modelling techniques for genomics. Nature Reviews Genetics, 20, 389–403. https://doi.org/10.1038/s41576-019-0122-6.

• Eraslan, G., Avsec, Ž., Gagneur, J., & Theis, F. J. (2019). Deep learning: New computational modelling techniques for genomics. Nature Reviews Genetics, 20, 389–403. https://doi.org/10.1038/s41576-019-0122-6

• Esteva, A., Chou, K., Yeung, S., et al. (2021). Deep learning-enabled medical computer vision. npj Digital Medicine, 4, 5. https://doi.org/10.1038/s41746-020-00376-2

• Esteva, A., Kuprel, B., Novoa, R. A., et al. (2017). Dermatologist-level classification of skin cancer with deep neural networks. Nature, 542, 115–

118. https://doi.org/10.1038/nature21056

• Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., & Thrun, S. (2017). Dermatologist-level classification of skin cancer with deep neural networks. Nature, 542, 115–118. https://doi.org/10.1038/nature21056.

• European Union. (2024). Regulation (EU) 2024/1689 laying down harmonised rules on artificial intelligence (Artificial Intelligence Act).

• European Union. (2024). Regulation (EU) 2024/1689 of the European Parliament and of the Council laying down harmonised rules on artificial intelligence (Artificial Intelligence Act). Official Journal of the European Union.

• FDA-approved artificial intelligence and machine learning-enabled medical devices in general surgery: A review based on regulatory panel classification. (2026). Surgery, 190, 109846. https://doi.org/10.1016/j.surg.2025.109846

• Food and Agriculture Organization of the United Nations (FAO). (2017). Can Artificial Intelligence help improve agricultural productivity? FAO e- Agriculture.

• Food and Agriculture Organization of the United Nations (FAO). (2022). The State of Food and Agriculture 2022: Leveraging automation in agriculture for transforming agrifood systems. FAO.

• Food and Agriculture Organization of the United Nations. (2021). Digital agriculture in action: Artificial intelligence for agriculture. FAO & ITU. 153

• Food and Agriculture Organization of the United Nations. (2026). Agricultural water management. FAO.

• Food and Agriculture Organization of the United Nations. (2026). Irrigation management. FAO.

• Food and Drug Administration (FDA). (2025). Considerations for the use of artificial intelligence to support regulatory decision-making for drug and biological products: Draft guidance for industry and other interested parties. U.S. Department of Health and Human Services.

• Food and Drug Administration (FDA). (2026). Artificial intelligence for drug development. U.S. Department of Health and Human Services.

• Fu, Z., Yang, Y., Chung, M. K., & Cheng, F. (2026). Artificial intelligence to guide repurposing of drugs. Annual Review of Medicine, 77, 381–398. https://doi.org/10.1146/annurev-med-050224-122802.

• Fushimi, K., Nakai, Y., Nishi, A., et al. (2025). Development of the autonomous lab system to support biotechnology research. Scientific Reports, 15, 6648. https://doi.org/10.1038/s41598-025-89069-y

• Gangwal, A., & Lavecchia, A. (2024). Unleashing the power of generative AI in drug discovery. Drug Discovery Today, 103992. https://doi.org/10.1016/j.drudis.2024.103992.

• Gangwal, A., Ansari, A., Ahmad, I., Azad, A. K., & Wan Sulaiman, W. M. A. (2024). Current strategies to address data scarcity in artificial intelligence-based drug discovery: A comprehensive review. Computers in Biology and Medicine, 179, 108734. https://doi.org/10.1016/j.compbiomed.2024.108734.

• Gao, H., Zhangzhong, L., Zheng, W., & Chen, G. (2023). How can agricultural water production be promoted? A review on machine learning for irrigation. Journal of Cleaner Production, 414, 137687. https://doi.org/10.1016/j.jclepro.2023.137687.

• Gbashi, S., & Njobeh, P. B. (2024). Enhancing food integrity through artificial intelligence and machine learning: A comprehensive review. Applied Sciences, 14(8), 3421. https://doi.org/10.3390/app14083421

• Ghislat, G., Hernandez-Hernandez, S., Piyawajanusorn, C., & Ballester, P. J. (2024). Data-centric challenges with the application and adoption of artificial intelligence for drug discovery. Expert Opinion on Drug Discovery, 19(11), 1297–1307. https://doi.org/10.1080/17460441.2024.2403639. 154

• Goodfellow, I., Bengio, Y., & Courville, A. (2016). Deep Learning. MIT Press.

• Gorgulla, C., et al. (2023). Recent developments in structure-based virtual screening approaches. Current Opinion in Structural Biology.

• Goshisht, M. K. (2024). Machine learning and deep learning in synthetic biology: Key architectures, applications, and challenges. ACS Omega, 9, 9921–9945. https://doi.org/10.1021/acsomega.3c05913

• Government of India. (2023). The Digital Personal Data Protection Act,

2023. India Code, Ministry of Law and Justice.

• Gulshan, V., Peng, L., Coram, M., et al. (2016). Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA, 316(22), 2402–2410. https://doi.org/10.1001/jama.2016.17216
• Gupta, R. S., Wood, C. E., Engstrom, T., Pole, J. D., & Shrapnel, S. (2025). Quantum machine learning for digital health? A systematic review. npj Digital Medicine, 8. https://doi.org/10.1038/s41746-025-01597-z
• Han, H., Liu, Z., Li, J., et al. (2024). Challenges in remote sensing based climate and crop monitoring: Navigating the complexities using AI. Journal of Cloud Computing, 13, 34. https://doi.org/10.1186/s13677-023-00583-8
• Hasin, Y., Seldin, M., & Lusis, A. (2017). Multi-omics approaches to disease. Genome Biology, 18, 83. https://doi.org/10.1186/s13059-017- 1215-1
• Hassan, M. A., et al. (2024). A review of machine learning techniques in agroclimatic studies. Agriculture, 14(3), 481. https://doi.org/10.3390/agriculture14030481
• Hassan, M. M., Xu, Y., Sayada, J., Zareef, M., Shoaib, M., Chen, X., Li, H., & Chen, Q. (2025). Progress of machine learning-based biosensors for the monitoring of food safety: A review. Biosensors and Bioelectronics, 267, 116782. https://doi.org/10.1016/j.bios.2024.116782
• Hermann, J., Spencer, J., Choo, K., Mezzacapo, A., Foulkes, W. M. C., Pfau, D., Carleo, G., & Noé, F. (2023). Ab initio quantum chemistry with neural-network wavefunctions. Nature Reviews Chemistry, 7, 692–709. https://doi.org/10.1038/s41570-023-00516-8
• Hu, W.-H., Sun, H.-M., & Wei, Y.-Y. (2025). Global infectious disease early warning models: An updated review and lessons from the COVID-19 155

pandemic. Infectious Disease Modelling, 10(2), 410–422. https://doi.org/10.1016/j.idm.2024.12.001.

• Huang, J. D., Ramsey, E., Condell, J., & others. (2022). Applying artificial intelligence to wearable sensor data to diagnose and predict cardiovascular disease: A review. Sensors, 22.

• Huang, K., Chandak, P., Wang, Q., et al. (2024). A foundation model for clinician-centered drug repurposing. Nature Medicine, 30, 3601–3613. https://doi.org/10.1038/s41591-024-03233-x.

• Indian Council of Medical Research (ICMR). (2023). Ethical guidelines for application of artificial intelligence in biomedical research and healthcare. Government of India.

• Intelligent Pharmacy. (2024). AI's role in revolutionizing personalized medicine by reshaping pharmacogenomics and drug therapy. Intelligent Pharmacy, 2(5), 643–650. https://doi.org/10.1016/j.ipha.2024.08.005

• Isoko, K., Cordiner, J. L., Kis, Z., & Moghadam, P. Z. (2024). Bioprocessing 4.0: A pragmatic review and future perspectives. Digital Discovery, 3, 1662–1681. https://doi.org/10.1039/D4DD00127C

• Jabed, M. A., & Murad, M. A. A. (2024). Crop yield prediction in agriculture: A comprehensive review of machine learning and deep learning approaches, with insights for future research and sustainability. Heliyon, 10(24), e40836. https://doi.org/10.1016/j.heliyon.2024.e40836

• Jaganathan, K., Kyriazopoulou Panagiotopoulou, S., McRae, J. F., et al. (2019). Predicting splicing from primary sequence with deep learning. Cell, 176(3), 535–548.e24. https://doi.org/10.1016/j.cell.2018.12.015.

• Jiménez-Luna, J., Grisoni, F., Schneider, G., & others. (2021). Deep learning in virtual screening: Recent applications and developments. International Journal of Molecular Sciences, 22(9), 4435.

• Jin, W., et al. (2023). Machine learning for metabolic pathway optimization: A review. Frontiers in Bioengineering and Biotechnology.

• Jumper, J., Evans, R., Pritzel, A., et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596, 583–589. https://doi.org/10.1038/s41586-021-03819-2.

• Jumper, J., Evans, R., Pritzel, A., et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596, 583–589. https://doi.org/10.1038/s41586-021-03819-2 156

• Katsoulakis, E., Wang, Q., Wu, H., et al. (2024). Digital twins for health: A scoping review. npj Digital Medicine, 7, 77. https://doi.org/10.1038/s41746-024-01073-0.

• Khan, M. A., et al. (2024). Artificial intelligence applications to genomic data in cancer research: A review of recent trends and emerging areas. Discover Analytics.

• Kučera, T. (2016). Virtual screening in drug design-Overview of most frequent techniques. Medicinal and Medical Sciences Letters, 85(2), 75–79. https://doi.org/10.31482/mmsl.2016.014

• Larkin, P. M. K., et al. (2021). Emerging applications of machine learning in food safety. Annual Review of Food Science and Technology, 12, 513–

538. https://doi.org/10.1146/annurev-food-071720-024112

• Lawson, C. E., Martí, J. M., Radivojevic, T., et al. (2021). Machine learning for metabolic engineering: A review. Metabolic Engineering, 63, 34–52. https://doi.org/10.1016/j.ymben.2020.10.005
• LeCun, Y., Bengio, Y., & Hinton, G. (2015). Deep learning. Nature, 521, 436–444. https://doi.org/10.1038/nature14539
• Leong, S. X., Griesbach, C. E., Zhang, R., et al. (2025). Steering towards safe self-driving laboratories. Nature Reviews Chemistry, 9, 707–722.
• Li, Q., Hu, Z., Wang, Y., Li, L., Fan, Y., King, I., Song, L., & Li, Y. (2024). Progress and opportunities of foundation models in bioinformatics. arXiv preprint arXiv:2402.04286.
• Libbrecht, M. W., & Noble, W. S. (2015). Machine learning applications in genetics and genomics. Nature Reviews Genetics, 16(6), 321–332. https://doi.org/10.1038/nrg3920
• Litjens, G., Kooi, T., Bejnordi, B. E., et al. (2017). A survey on deep learning in medical image analysis. Medical Image Analysis, 42, 60–88. https://doi.org/10.1016/j.media.2017.07.005
• Mahmud, M. I., & Banerjee, T. (2026). Artificial intelligence in genomics: A comprehensive survey of methods, resources, challenges, and prospects. Briefings in Bioinformatics, 27(3), bbag229. https://doi.org/10.1093/bib/bbag229
• McClymont, H., Lambert, S. B., Barr, I., & Vardoulakis, S. (2024). Internet-based surveillance systems and infectious diseases prediction: An 157

updated review of the last 10 years and lessons from the COVID-19 pandemic. Journal of Epidemiology and Global Health, 14, 645–657.

• Meskó, B., & Görög, M. (2020). A short guide for medical professionals in the era of artificial intelligence. NPJ Digital Medicine, 3, 126.
• Min, S., Lee, B., & Yoon, S. (2017). Deep learning in bioinformatics. Briefings in Bioinformatics, 18(5), 851–869. https://doi.org/10.1093/bib/bbw068
• Mohanty, S. P., Hughes, D. P., & Salathé, M. (2016). Using deep learning for image-based plant disease detection. Frontiers in Plant Science, 7, 1419. https://doi.org/10.3389/fpls.2016.01419.
• Mondal, P. P., Galodha, A., Verma, V. K., et al. (2023). Review on machine learning-based bioprocess optimization, monitoring, and control systems. Bioresource Technology, 370, 128523. https://doi.org/10.1016/j.biortech.2022.128523
• Morley, J., Machado, C. C. V., Burr, C., Cowls, J., Joshi, I., Taddeo, M., & Floridi, L. (2020). The ethics of AI in health care: A mapping review. Social Science & Medicine, 260, 113172. https://doi.org/10.1016/j.socscimed.2020.113172
• Moshawrab, M., Adda, M., & Bouzouane, A. (2023). Smart wearables for the detection of cardiovascular diseases: A systematic literature review. Sensors, 23(2), 828. https://doi.org/10.3390/s23020828
• National Institute of Standards and Technology. (2023). Artificial Intelligence Risk Management Framework (AI RMF 1.0) (NIST AI 100-1). U.S. Department of Commerce.
• National Institute of Standards and Technology. (2023). NIST AI Risk Management Framework. U.S. Department of Commerce.
• Ngugi, H. N., Ezugwu, A. E., Akinyelu, A. A., et al. (2024). Revolutionizing crop disease detection with computational deep learning: A comprehensive review. Environmental Monitoring and Assessment, 196,

302. https://doi.org/10.1007/s10661-024-12454-z.

• Notin, P., Rollins, N., Gal, Y., et al. (2024). Machine learning for functional protein design. Nature Biotechnology, 42, 216–228. https://doi.org/10.1038/s41587-024-02127-0 158

• Notin, P., Rollins, N., Gal, Y., Sander, C., & Marks, D. S. (2024). Machine learning for functional protein design. Nature Biotechnology, 42, 216–228. https://doi.org/10.1038/s41587-024-02127-0.

• Obermeyer, Z., Powers, B., Vogeli, C., & Mullainathan, S. (2019). Dissecting racial bias in an algorithm used to manage the health of populations. Science, 366(6464), 447–453. https://doi.org/10.1126/science.aax2342

• OECD. (2015). Health Data Governance: Privacy, Monitoring and Research. OECD Publishing. https://doi.org/10.1787/9789264244566-en

• Olawade, D. B., Kade, A., Egbon, E., Usman, S. O., Fapohunda, O., Ijiwade, J., & Ogbonna, C. E. (2025). Bioinformatics and artificial intelligence in genomic data analysis: Current advances and future directions. Molecular Genetics and Genomics, 300, 111. https://doi.org/10.1007/s00438-025-02314-x

• Pacal, I., Kunduracioglu, I., Alma, M. H., et al. (2024). A systematic review of deep learning techniques for plant diseases. Artificial Intelligence Review, 57, 304. https://doi.org/10.1007/s10462-024-10944-7.

• Parra-López, C., Ben Abdallah, S., Garcia-Garcia, G., et al. (2025). Digital technologies for water use and management in agriculture: Recent applications and future outlook. Agricultural Water Management.

• Patro, R., Duggal, G., Love, M. I., Irizarry, R. A., & Kingsford, C. (2017). Salmon provides fast and bias-aware quantification of transcript expression. Nature Methods, 14, 417–419. https://doi.org/10.1038/nmeth.4197.

• Peng, J., et al. (2026). Machine learning methods for small data and upstream bioprocessing applications: A comprehensive review. Biotechnology Advances, 87, 108749. https://doi.org/10.1016/j.biotechadv.2025.108749.

• Peterson, J. F., Feng, Q., Malin, B. A., & Wei, W.-Q. (2024). Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer’s disease with real-world clinical validation. npj Digital Medicine, 7, 46. https://doi.org/10.1038/s41746-024-01038-3.

• Pinzi, L., & Rastelli, G. (2019). Molecular docking: Shifting paradigms in drug discovery. International Journal of Molecular Sciences, 20(18), 4339.

• Pirmohamed, M. (2023). Pharmacogenomics: Current status and future perspectives. Nature Reviews Genetics, 24(6), 350–362. https://doi.org/10.1038/s41576-022-00572-8 159

• Poplin, R., Chang, P.-C., Alexander, D., et al. (2018). A universal SNP and small-indel variant caller using deep neural networks. Nature Biotechnology, 36, 983–987. https://doi.org/10.1038/nbt.4235.

• Poplin, R., Chang, P.-C., Alexander, D., Schwartz, S., Colthurst, T., Ku, A., Newburger, D., Dijamco, J., Nguyen, N., Afshar, P. T., Gross, S. S., Dorfman, L., McLean, C. Y., & DePristo, M. A. (2018). A universal SNP and small-indel variant caller using deep neural networks. Nature Biotechnology, 36, 983–987. https://doi.org/10.1038/nbt.4235

• Powell, D. (2024). Walk, talk, think, see and feel: Harnessing the power of digital biomarkers in healthcare. npj Digital Medicine, 7, 45.

• Precision agriculture in the age of AI: A systematic review of machine learning methods for crop disease detection. (2025). Smart Agricultural Technology, 12, 101491.

• Rajpurkar, P., Chen, E., Banerjee, O., & Topol, E. J. (2022). AI in health and medicine. Nature Medicine, 28, 31–38. https://doi.org/10.1038/s41591- 021-01614-0

• Rapp, J. T., Bremer, B. J., & Romero, P. A. (2024). Self-driving laboratories to autonomously navigate the protein fitness landscape. Nature Chemical Engineering, 1, 97–107. https://doi.org/10.1038/s44286-023- 00002-4

• Ream, M., & Prather, K. L. J. (2024). Engineered autonomous dynamic regulation of metabolic flux. Nature Reviews Bioengineering, 2, 233–243.

• Reardon, B., Culhane, A. C., & Van Allen, E. M. (2026). Convergence of machine learning and genomics for precision oncology. Nature Reviews Cancer, 26, 217–229.

• Remote sensing and artificial intelligence for crop pest and disease monitoring: A systematic review of sensing technologies, AI approaches, and barriers to field adoption. (2026). Smart Agricultural Technology, 14, 102279.

• Richardson, J. S., Read, R. J., et al. (2024). AlphaFold predictions are valuable hypotheses and accelerate but do not replace experimental structure determination. Nature Methods, 21, 110–116.

• Rodríguez, A., Kamarthi, H., Agarwal, P., Ho, J., Patel, M., Sapre, S., & Prakash, B. A. (2024). Machine learning for data-centric epidemic forecasting. Nature Machine Intelligence, 6, 1122–1131. 160

• Sadee, W., Wang, D., Hartmann, K., et al. (2023). Pharmacogenomics: Driving personalized medicine. Pharmacological Reviews, 75(4), 789–814. https://doi.org/10.1124/pharmrev.122.000810

• Sadybekov, A. V., & Katritch, V. (2023). Computational approaches streamlining drug discovery. Nature, 616, 673–685. https://doi.org/10.1038/s41586-023-05905-z

• Saeidi, H., et al. (2022). A systematic review of robotic surgery: From supervised paradigms to fully autonomous robotic approaches. International Journal of Medical Robotics and Computer Assisted Surgery.

• Schirone, M., D’Ambrosio, G., & Paparella, A. (2026). Artificial intelligence in foodborne pathogen detection from sensing to food safety systems: A systematic review. Foods, 15(14), 2562. https://doi.org/10.3390/foods15142562

• Schoenherr, J. R., et al. (2024). Ethical considerations in the design and conduct of clinical trials of artificial intelligence. JAMA Network Open.

• Shajari, S., Kuruvinashetti, K., Komeili, A., & Sundararaj, U. (2023). The emergence of AI-based wearable sensors for digital health technology: A review. Sensors, 23(23), 9498. https://doi.org/10.3390/s23239498.

• Shen, M.-d., Chen, S.-b., & Ding, X.-d. (2024). The effectiveness of digital twins in promoting precision health across the entire population: A systematic review. npj Digital Medicine, 7, 145. https://doi.org/10.1038/s41746-024-01146-0.

• Shukla, K., Nagpal, S., & Vyas, A. (2026). Opportunities of digital twin in controlling and monitoring microbial processes in food fermentation. Systems Microbiology and Biomanufacturing, 6(3), 56. https://doi.org/10.1007/s43393-026-00454-8

• Silva, M. P. da, Correa, S. P. L. P., Schaefer, M. A. R., Reis, J. C. S., Nunes, I. M., dos Santos, J. A., & Oliveira, H. N. (2025). Advancing agricultural remote sensing: A comprehensive review of deep supervised and self-supervised learning for crop monitoring. Pattern Recognition Letters, 133, 104434.

• Smaldone, A. M., Shee, Y., Kyro, G. W., Xu, C., Vu, N. P., Dutta, R., Farag, M. H., Galda, A., Kumar, S., Kyoseva, E., & Batista, V. S. (2025). Quantum machine learning in drug discovery: Applications in academia and pharmaceutical industries. Chemical Reviews, 125(12), 5436–5460. https://doi.org/10.1021/acs.chemrev.4c00678 161

• Su, J., Xin, C., Shang, A., Wu, S., Xie, Z., Xiong, R., Xu, X., Zhang, C., Chen, G., Chan, Y.-T., Tang, G., Wang, N., Xu, Y., & Feng, Y. (2026). Artificial intelligence in drug discovery and development: Current landscape, challenges, and future perspectives. Critical Reviews in Oncology/Hematology. https://doi.org/10.1016/j.critrevonc.2026.105461.

• Suay-García, B., & Falcó, A. (2026). Topological deep learning for drug-target interaction, virtual screening, and docking scoring: A practical, benchmark-driven review. Briefings in Bioinformatics, 27(4), bbag370. https://doi.org/10.1093/bib/bbag370

• Sultana, H., et al. (2026). AI in genomics: From variant calling to multi-omics integration. BioEssays. https://doi.org/10.1002/bies.70160.

• Sultana, H., et al. (2026). AI in genomics: From variant calling to multi-omics integration. BioEssays. https://doi.org/10.1002/bies.70160

• Tabassi, E. (2023). Artificial intelligence risk management framework (AI RMF 1.0). National Institute of Standards and Technology. https://doi.org/10.6028/NIST.AI.100-1

• Taha, M. O., & Daoud, S. (2026). Innovative integration of molecular docking and machine learning for drug discovery: From virtual screening to nanomolar inhibitors. Chemical Communications. https://doi.org/10.1039/D5CC06025G

• Tang, C., Yi, W., Occhipinti, E., et al. (2024). A roadmap for the development of human body digital twins. Nature Reviews Electrical Engineering, 1, 199–207.

• Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25, 44–56. https://doi.org/10.1038/s41591-018-0300-7

• Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25, 44–56. https://doi.org/10.1038/s41591-018-0300-7.

• Trends in machine and deep learning techniques for plant disease identification: A systematic review. (2024). Agriculture, 14(12), 2188.

• Tropsha, A., Isayev, O., Varnek, A., Schneider, G., & Cherkasov, A. (2024). Integrating QSAR modelling and deep learning in drug discovery: The emergence of deep QSAR. Nature Reviews Drug Discovery, 23, 141–

155. https://doi.org/10.1038/s41573-023-00832-0 162